For the first time, the US has approved a nasal spray flu vaccine that can be self-administered
FluMist is the first vaccine to prevent influenza (commonly known as the flu) that does not need to be administered by a health care provider.
The United States has approved a nasal spray vaccine to fight influenza (flu) illnesses caused by influenza virus subtypes A and B for people ages 2 to 49 years old.
This nasal spray, called FluMist, is not a prescription drug and can be self-administered or administered by a caregiver. It is sprayed into the nose and has been used safely and effectively for many years.
FluMist is the first vaccine to prevent influenza (commonly known as the flu) that does not need to be administered by a health care provider.
“Today’s approval of the first self- or caregiver-administered influenza vaccine provides a new option for individuals and families to receive a safe and effective seasonal influenza vaccine with greater convenience, flexibility and accessibility,” said Peter Marks, MD, director of the FDA’s Center for Biologics Evaluation and Research.
Flu is a common infectious respiratory disease caused by the influenza virus, which usually spreads during the monsoon and winter seasons. Symptoms such as body aches, fever, cough and sore throat often appear suddenly and can range from mild to severe.
Flu can lead to serious complications, especially in high-risk groups such as the elderly, young children and people with long-term health problems.
Vaccines are available every flu season to prevent the disease. It is manufactured by AstraZeneca’s MedImmune, LLC.
FluMist, a nasal spray vaccine that uses weakened live influenza virus, requires a prescription and can be given by a healthcare provider or caregiver to anyone 18 years of age or older.
Common side effects include fever in young children, nasal congestion in people aged 2 to 49 years, and sore throat in adults.
People who want to use it on their own can order FluMist through an online pharmacy after completing a screening assessment.
The vaccine can then be given to a designated household member at their convenience. Caregivers should give FluMist to individuals ages 2 to 17, as they are not allowed to administer it themselves.
The vaccine package contains detailed instructions for storage, use, and disposal to ensure proper administration.
“It was initially approved by the FDA in 2003 for use in individuals ages 5 to 49, and in 2007 the FDA also approved the use of FluMist in children ages 2 to 5,” the FDA reports.
